我要投票 康缘在中草药行业中的票数:125
· 外 推 电 报 ·
2025-03-11 02:52:03 星期二

【康缘是哪个国家的品牌?】

康缘是什么牌子?「康缘」是 江苏康缘药业股份有限公司 旗下著名品牌。该品牌发源于江苏,由创始人肖伟在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康缘品牌出海!通过在本页面挂载康缘品牌的产品链接和联系邮箱,可以提高康缘产品曝光!跨境电商爆单神器,目前只要100元/年哦~

充满活力的创新型制药企业--江苏康缘药业股份有限公司是一家集中药研发、生产、贸易为一体的大型中药企业,是国家中药现代化示范企业、国家重点高新技术企业、国内A股上市公司、国家创新型企业,全国制药工业百强企业,获国家“质量管理先进企业”,“守合同重信用企业”等荣誉称号,“康缘”商标为国家驰名商标。

公司坚持以科研创新为先导,不断提升企业自主创新实力。企业设立博士后科研工作站、江苏省院士工作站,成立康缘现代中药研究院,拥有一支包括6名博士后、12名博士、80余名硕士在内的180多名科研人员组成的研究队伍;先后与中国医学科学院药物研究所、中科院上海有机化学研究所、大连工业大学等科研院所联合建立了十余个共建实验室,并在美国建立了创新药物研发公司,自主创新能力位居国内同行前列,发明专利授权量在同行业中名列前茅。2002年康缘药业被批准设立博士后科研工作站,2005年公司研发中心被认定为国家级企业技术中心。2010年1月康缘研究院被国家科技部批准建设“中药制药过程新技术国家重点实验室”,进入我国中医药创新体系国家队行列。

康缘药业拥有国内最大的智能化中药材提取生产线,具有年处理生药材10000吨的能力;拥有通过国家GMP验证的制剂车间,配套完善的备料中心、质量检测中心、动力中心、智能管理中心,设有硬胶囊、软胶囊、小容量注射剂、冻干粉针剂等十三条最先进的生产线,具备年生产硬胶囊12亿粒、软胶囊3.4亿粒、口服液1亿支、小容量注射剂5亿支、冻干粉针剂600万支、片剂15亿片、颗粒剂1000吨的能力。

康缘药业全力推行专业化、学术化营销,建立了一支高素质、专业化1600余人的营销队伍,在全国29个省市建立了34个销售分公司、226多个中心办事处,与全国146家医药商业公司建立了长期稳定的业务关系,产品覆盖近7000家县级以上医疗单位。

英文翻译:Jiangsu Kangyuan Pharmaceutical Co., Ltd., a dynamic and innovative pharmaceutical enterprise, is a large-scale Chinese medicine enterprise integrating research and development, production and trade of traditional Chinese medicine. It is a national modern demonstration enterprise of traditional Chinese medicine, a national key high-tech enterprise, A-share listed company, a national innovative enterprise, and one of the top 100 pharmaceutical enterprises in China, It has won the honorary titles of "advanced quality management enterprise", "contract abiding and trustworthy enterprise" and "Kangyuan" trademark is a national well-known trademark. The company adheres to scientific research and innovation as the guide, and constantly improves the independent innovation strength of the enterprise. The company has set up postdoctoral research station, Jiangsu academician workstation, and Kangyuan modern Chinese Medicine Research Institute. It has a research team of more than 180 researchers, including 6 postdoctoral, 12 doctors, and more than 80 masters. It has been jointly built with the Institute of medicine of Chinese Academy of Medical Sciences, Shanghai Institute of organic chemistry of Chinese Academy of Sciences, Dalian University of technology and other research institutes More than ten co built laboratories have been set up, and innovative drug R & D companies have been established in the United States. The independent innovation ability ranks in the forefront of domestic peers, and the amount of invention patent authorization ranks first in the same industry. In 2002, Kangyuan pharmaceutical was approved to set up a postdoctoral research workstation, and in 2005, the company's R & D center was recognized as a national enterprise technology center. In January 2010, Kangyuan Research Institute was approved by the Ministry of science and technology of the people's Republic of China to build the "National Key Laboratory of new technology in the pharmaceutical process of traditional Chinese medicine", and entered the ranks of the national team of Chinese medicine innovation system. Kangyuan Pharmaceutical Co., Ltd. has the largest intelligent production line of Chinese herbal medicine extraction in China, with an annual capacity of 10000 tons of raw herbs. It has a preparation workshop certified by the national GMP, a complete set of material preparation center, quality inspection center, power center, intelligent management center, and 13 most advanced production lines, including hard capsule, soft capsule, small volume injection, freeze-dried powder injection, It has the annual production capacity of 1.2 billion hard capsules, 340 million soft capsules, 100 million oral liquids, 500 million small volume injections, 6 million lyophilized powder injections, 1.5 billion tablets and 1000 tons of granules. Kangyuan pharmaceutical industry has made great efforts to promote professional and academic marketing, established a high-quality and professional marketing team of more than 1600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, established long-term and stable business relations with 146 pharmaceutical commercial companies across the country, with products covering nearly 7000 medical units above the county level.

本文链接: https://www.waitui.com/brand/0310949a5.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

我国科学家在抗烧结催化剂研究中取得新进展

36氪获悉,据中国科学技术大学消息,该校曾杰教授团队通过构筑纳米岛结构催化剂,攻克了甲烷干重整反应中催化剂极易烧结失活的难题。相关研究成果3月10日发表于国际学术期刊《自然∙材料》。超细金属纳米颗粒因其超高的原子利用率,在多相催化领域备受青睐。然而,在催化反应过程中,这些纳米颗粒极易受到高温等影响,从而自发聚集并导致活性降低,该过程被称作烧结。发展超细金属纳米颗粒的抗烧结策略,是催化科学领域亟待解决的关键难题。

52分钟前

蔚蓝锂芯:2024年净利润4.88亿元,同比增长246.43%

36氪获悉,蔚蓝锂芯公告,公司实现营业总收入67.56亿元,同比增长29.38%;实现净利润5.44亿元,同比增长171.98%;归属于上市公司股东的净利润4.88亿元,同比增长246.43%。公司拟以2024年12月31日总股本1,152,046,537股为基数,向全体股东每10股派发现金红利0.65元(含税)。

52分钟前

美股大型科技股盘前全线下跌,特斯拉跌超3%

36氪获悉,美股大型科技股盘前全线下跌,截至发稿,特斯拉、Arm跌超3%,英伟达、亚马逊、谷歌、Meta跌超2%,苹果、微软、奈飞跌超1%。

52分钟前

热门中概股美股盘前普跌,B站跌超4%

36氪获悉,热门中概股美股盘前普跌,截至发稿,B站跌超4%,阿里巴巴跌超3%,京东、爱奇艺、腾讯音乐、蔚来、理想汽车、小鹏汽车跌超2%,拼多多、百度跌超1%。

52分钟前

新产业:红杉聚业拟减持不超1%公司股份

36氪获悉,新产业公告,公司持股5%以上的股东天津红杉聚业股权投资合伙企业(有限合伙)计划自公告之日起15个交易日后的3个月内通过大宗交易方式减持公司股份不超过总股本的1%。若公司在减持计划实施期间发生送股、资本公积转增股本、配股等变动事项,减持股份数量进行相应调整。减持原因为自身资金需求。

53分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询